Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in patients with unstable angina and non-Q-wave myocadial infarction
The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris ( UAP ) or non-Q-wave myocardial infa rct ion ( NQMI ) can influence the serum level of C-reactive protein ( CRP ) , interleukin-6 ( IL-6 ) and interleukin-8 ( IL-8 ) 24 h later . Forty-four patients with rest chest pain and subendocardial ischemia on ECG were r and omized to receive cerivastatin 0.3 mg at the time of admission ( group C+ ) to st and ard therapy or to remain just on st and ard therapy ( group C− ) . Blood sample s for determination of troponin I ( TI ) , CRP , IL-6 and IL-8 were collected at admission ( entry level ) and 24 h later ( final level ) . Patients with non-physiological baseline levels of TI  , as well as patients with progression to Q wave MI were excluded . All baseline , clinical and demographic data and final values of TI were comparable in the two groups . In patients treated with cerivastatin ( group C+ , n = 13 ) we observed decrease in the CRP level ( −6.73 ± 3.93 mg/L ) ; on the other h and , in group C− ( n = 17 ) the CRP level increased ( + 7.92 ± 2.77 mg/L , p = 0.004 ) . Similar differences were observed also in IL-6 : in group C+ the level was significantly reduced as compared with the increase in group C− ( −0.76 ± 0.52 vs. 4.58 ± 1.49 ng/L , p = 0.005 ) . The level of IL-8 was not affected . Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI ; this might positively influence their prognosis . Nevertheless , further studies are needed to support this hypothesis
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .